Skip to main content
SpringerLink
Log in

Side Effects of 131I for Therapy of Differentiated Thyroid Carcinoma

  • Chapter
  • First Online:
Thyroid Cancer

Abstract

The use of radioactive iodine (131I) for remnant ablation, adjuvant treatment, and treatment of metastases from differentiated thyroid carcinoma may be associated with side effects in numerous organ systems. Although many articles address the side effects of 131I, the characterizations of these effects vary widely because of a host of different factors. This chapter attempts to consolidate the literature by presenting, where appropriate, (1) the spectrum of signs and symptoms, as well as the frequency and severity of side effects; (2) a review of selected articles; (3) a discussion of preventive measures to reduce the frequency and severity of side effects; and (4) a discussion of the medical management when selected side effects do occur.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of 131I dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.

    CAS  PubMed  Google Scholar 

  2. Alexander C, Bader JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose 131I therapy for thyroid carcinoma. J Nucl Med. 1998;39:1551–4.

    CAS  PubMed  Google Scholar 

  3. Chiu AC, Delpass ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:3637–42.

    Article  CAS  PubMed  Google Scholar 

  4. Holmquest DL, Lake P. Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-I31. J Nucl Med. 1976;17:307–9.

    CAS  PubMed  Google Scholar 

  5. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med. 1986;27:637–40.

    CAS  PubMed  Google Scholar 

  6. Hurley JR, Becker DV. The use of 131I in the management of thyroid cancer. In: Freeman LM, Weissman HS, editors. Nuclear medicine annual 1983. New York: Raven Press; 1983. p. 329–84.

    Google Scholar 

  7. Grayson RR. Factors which influence the radioactive iodine thyroidal uptake test. Am J Med. 1960;24:397–415.

    Article  Google Scholar 

  8. Bedikian AY, Valdivieso M, Heilbrun LK, et al. Glycerol: a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease. Cancer Treat Rep. 1978;62:1081–3.

    CAS  PubMed  Google Scholar 

  9. Murakami H, Kawahara N, Yahata T, et al. Radiation myelopathy after radioactive iodine therapy for spine metastasis. Br J Radiol. 2008;79:e45–9.

    Article  Google Scholar 

  10. Yevgeniya SK, Sergiy VK, Caroll NM, Felger E, Links TP, Bonichon F, Preul MC, Sonntag VKH, Van Nostrand D, Burman KD, Boyle LM. Spinal metastases due to thyroid carcinoma: an analysis of 202 patients. Thyroid. 2014;24:1443-55.

    Google Scholar 

  11. Spitzweg C, Joba W, Schriever IK, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab. 1999;84:4178–84.

    CAS  PubMed  Google Scholar 

  12. Morgenstern KE, Vadysirisack DD, Zhang Z, et al. Express of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in 131I treated patients. Ophthalmic Plast Reconstr Surg. 2005;21:337–44.

    Article  Google Scholar 

  13. Zettinig G, Hanselmayer G, Fueger B, et al. Long-term impairment of the lacrimal glands after 131I therapy: a cross-sectional study. Eur J Nucl Med. 2002;29:1428–32.

    Article  CAS  Google Scholar 

  14. Fard-Esfahni A, Mirshekarpour H, Fallahi B, et al. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med. 2007;32:696–9.

    Article  Google Scholar 

  15. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after 131I therapy. J Nucl Med. 2001;42:738–43.

    CAS  PubMed  Google Scholar 

  16. Koca G, Acar U, Atilgan HI, Acar DE, Altiparmak UE, Demirel K, Yalnizi-Akkay Z, Ustun H, Korkmas M, Ornek F. Changes in conjunctival cytology and tear function tests with radioiodine treatment for hyperthyroidism. Ann Nucl Med. 2013;27:694–9.

    Article  CAS  PubMed  Google Scholar 

  17. Bakheet SMB, Hammami MM, Hemidan A, et al. 131I secretion in tears. J Nucl Med. 1998;39:1452–4.

    CAS  PubMed  Google Scholar 

  18. Kloos RT, Duvuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:5817–20.

    Article  CAS  PubMed  Google Scholar 

  19. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I-131 therapy. Ophthal Plast Reconstr Surg. 2004;20:1126–9.

    Article  Google Scholar 

  20. Fard-Esfahani A, Farzanefar S, Fallahi B, Beiki D, Saghari M, Emami-Ardekani A, Majdi M, Eftekhari M. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer. Nucl Med Commun. 2012;33:1077–80.

    Article  CAS  PubMed  Google Scholar 

  21. Orquiza M, Khorjekar G, Schneider M, Kulkarni K, Garcia C, Acio E, Burman K, Wartofsky L, Van Nostrand D. Epiphora and xerophthalmia after 131I therapy: the frequency, time of onset, severity, and duration. J Nucl Med. 2014;55:1933 (abstract).

    Google Scholar 

  22. Yuoness S, Rachinsky I, Driedger AA, et al. Differentiated thyroid cancer with epiphora: detection of nasolacrimal duct obstruction on I-131 SPECT/CT. Clin Nucl Med. 2011;36:1149–50.

    Article  PubMed  Google Scholar 

  23. Beutel J, Schroder C, von Hof K, Rades D, et al. Pharmacological prevention of radiation-induced dry eye: an experimental study in a rabbit model. Arch Clin Exp Ophthalmol. 2007;245:1347–55.

    Article  CAS  Google Scholar 

  24. Acar U, Atilgan HI, Acar DE, Yalniz-Akkaya Z, Yumusak N, Korkmaz M, Koca G. The effect of short-term vitamin E against radioiodine-induced early lacrimal gland damage. Ann Nucl Med. 2013;27:886–91.

    Article  CAS  PubMed  Google Scholar 

  25. Koca G, Yalniz-Akkaya Z, Gultekin SS, Yumuksak N, Demirel K, Korkmas M, et al. Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment. Rev Esp Med Nucl Imagen Mol. 2013;32:294–300.

    CAS  PubMed  Google Scholar 

  26. Ramakrishnan VR, Durairaj VD, Kingdom TT. Endoscopic management of acquired nasolacrimal duct obstruction secondary to radioactive radioiodine treatment for thyroid malignancy. J Allergy Ther. 2011;2:2–6.

    Article  Google Scholar 

  27. Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17:154–61.

    Article  PubMed  Google Scholar 

  28. Schiff L, Stevens CD, Molle WE, et al. Gastric (and salivary) excretion of 131I in man (preliminary report). J Natl Cancer Inst. 1947;7:349–54.

    CAS  PubMed  Google Scholar 

  29. Rice DH. Advances in diagnosis and management of salivary gland diseases. West J Med. 1984;140:238–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Myant NB. Iodine metabolism of salivary glands. Ann N Y Acad Sci. 1960;85:208.

    Article  CAS  PubMed  Google Scholar 

  31. Freinkel N, Ingbar SH. Concentration gradients for inorganic I-131 and chloride in mixed human saliva. J Clin Invest. 1953;32:1077–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Honour AJ, Myant NB, Rowlands EN. Secretion of 131I in digestive juices and milk in man. Clin Sci. 1952;11:449–62.

    CAS  PubMed  Google Scholar 

  33. Jhiang SM, Cho JY, Ryu KY, et al. An immunohistochemical study of Na+/I−symporter in human thyroid tissues and salivary gland tissues. Endocrinology. 1998;139:4416–9.

    CAS  PubMed  Google Scholar 

  34. Batsakis JG. Physiology. In: Cummings CW, Schuller DE, editors. Otolaryngology-head and neck surgery, vol. 2. St. Louis: Mosby-Year Book; 1998. p. 1210–22.

    Google Scholar 

  35. Donachi I. Biologic effects of radiation on the thyroid. In: Werner SC, Ingbar SH, editors. The thyroid. New York: Harper & Row; 1978. p. 274–83.

    Google Scholar 

  36. Goolden AWG, Mallard JR, Farran HEA. Radiation sialitis following 131I therapy. Br J Radiol. 1957;30:210–2.

    Article  CAS  PubMed  Google Scholar 

  37. Liu B, Huang R, Kuang A, Zhao Z, Zeng Y, Wang J, Tian R. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer. Med Phys. 2011;38:5412–9.

    Article  CAS  PubMed  Google Scholar 

  38. Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:884–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. La Perle KMD, Kim DC, Hall NC, Bobbey A, Shen DH, Nagy RS, Wakely PE, Lehman A, Jarjoura D, Jhiang SM. Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid. 2001;23:1029–35.

    Article  CAS  Google Scholar 

  40. Van Nostrand DV, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well differentiated thyroid carcinoma. J Nucl Med. 1986;27:1519–27.

    PubMed  Google Scholar 

  41. Kahn S, Waxman A, Ramanna L, et al. Transient radiation effects following high dose I-131 therapy for differentiated thyroid cancer (DTC). J Nucl Med. 1994;35:15P.

    Google Scholar 

  42. Albrecht HH, Creutzig H. Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose 131I therapy. Fortschr Rontgenstr. 1976;125:546–51.

    Article  CAS  Google Scholar 

  43. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialoadenitis following I-131 therapy for thyroid carcinoma: concise communication. J Nucl Med. 1984;25:755–8.

    CAS  PubMed  Google Scholar 

  44. Pan MS. Follow-up study of side effects for iodine-131 treatment in patients with differentiated thyroid cancer. J Nucl Med. 2004;5S:386P.

    Google Scholar 

  45. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol. 1987;103:318–24.

    Article  Google Scholar 

  46. Kharazi P, Van Nostrand D, Khorjekar G, Brennan M, McIver G, Mete M, Bloom G. Characterization of salivary gland side effects secondary to 131I therapy in patients with differentiated thyroid cancer: a national ThyCa: Thyroid Cancer Survivors’ Association, Inc. Survey. J Nucl Med. 2011;52S:1759 (abstract).

    Google Scholar 

  47. Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009;50:1605–10.

    Article  CAS  PubMed  Google Scholar 

  48. Hall J, Kharazi P, Van Nostrand D, Khorjekar G, Brennan M, McIver B, Mete M, Bloom G. Characterization of salivary gland side effects Up to 7 days after 131I therapy: updated report of the Thyroid Cancer Survivors’ Association, Inc. (ThyCa) National Survey. J Nucl Med. 2012;53(Suppl1):306.

    Google Scholar 

  49. Leeper R. Controversies in the treatment of thyroid carcinoma: the New York Memorial Hospital approach. Thyroid Today. 1982;4:1–6.

    Google Scholar 

  50. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose 131I ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med. 1996;21:780–2.

    Article  CAS  PubMed  Google Scholar 

  51. Brown AP, Greening WP, McCready VR, et al. 131I treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br J Radiol. 1984;57:323–7.

    Article  CAS  PubMed  Google Scholar 

  52. Schneyer LH, Tanchester D. Some oral aspects of radioactive iodine therapy for thyroid disease. N Y J Dent. 1954;24:308–9.

    Google Scholar 

  53. Mandel S, Mandel L. Persistent sialoadenitis after radioactive iodine therapy: report of two cases. J Oral Maxillofac Surg. 1999;57:738–41.

    Article  CAS  PubMed  Google Scholar 

  54. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with 131I. Int J Radiat Oncol Biol Phys. 1996;35:535–40.

    Article  CAS  PubMed  Google Scholar 

  55. Spiegel W, Reiners C, Borner W. Sialoadenitis following iodine-131 therapy for thyroid carcinoma. J Nucl Med. 1985;26:816.

    Google Scholar 

  56. Reiners C, Eichner R, Eilles C, et al. Kamera-funktionsszintigraphie der kopfspeicheldrusen nach hoch-dosierter radiojodtherapie bei schilddrusenkarzinoma patienten. In: Nuklearmedizin, Schmidt HAE, Riccabona G, editors. Stuttgart: Schattauer 1980. p. 477–81.

    Google Scholar 

  57. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13:265–71.

    Article  CAS  PubMed  Google Scholar 

  58. Laupa MS, Toth BB, Keene HJ. Effect of radioactive iodine therapy on salivary flow rates and oral streptococcus mutants prevalence in patients with thyroid cancer. Oral Surg Oral Med Oral Pathol. 1993;75:312–7.

    Article  CAS  PubMed  Google Scholar 

  59. Walters MA, Turtschi CP, Schindler C. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med. 2007;48:1620–5.

    Article  Google Scholar 

  60. Busnell DL, Boles MA, Kaufman GE, et al. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med. 1992;33:2214–21.

    Google Scholar 

  61. Davies AN. The management of xerostomia: a review. Eur J Cancer Care. 1997;6:209–14.

    Article  CAS  Google Scholar 

  62. Nakada K, Hirata K, Ishibashi T, et al. Cevimeline hydrochloride hydrate in treating salivary gland dysfunction following 131I therapy for thyroid cancer. J Nucl Med. 2004;45S:17P.

    Google Scholar 

  63. Ericson T, Lindberg A. Clinical trial of a saliva stimulating tablet SST. Tandjakartidningen. 1982;74:713–6.

    CAS  Google Scholar 

  64. Blom M, Lunderberg T. Long term follow up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis. 2000;6:15–24.

    Article  CAS  PubMed  Google Scholar 

  65. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. Gerodontology. 1986;5:75–99.

    Article  CAS  PubMed  Google Scholar 

  66. Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly; the SEE project. J Rheumatol. 1998;25:486–91.

    CAS  PubMed  Google Scholar 

  67. Mandel SJ, Mandel L. False-positive xerostomia following radioactive iodine treatment: case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:e43–7.

    Article  PubMed  Google Scholar 

  68. Kulkarni K, Kim SM, Intenzo C. Can salivary gland uptakes on a diagnostic I-131 scan predict acute salivary gland dysfunction in patients receiving 131I therapy for thyroid cancer? J Nucl Med. 2004;5S:291P.

    Google Scholar 

  69. Personal communications with Kristen L. Blair, Registered Dental Hygienist (RDH) and Janice Falvo, RDH, BS.

    Google Scholar 

  70. Silberstein E. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med. 2008;49:546–9.

    Article  PubMed  Google Scholar 

  71. Shaw LM, Bonner HS, Schuchter L, et al. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol. 1999;26:34–6.

    CAS  PubMed  Google Scholar 

  72. Werner-Wasik M. Future development of amifostine as a radioprotectant. Semin Oncol. 1999;26:129–1234.

    CAS  PubMed  Google Scholar 

  73. Dorr RT, Holmes BC. Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol. 1999;26:108–19.

    CAS  PubMed  Google Scholar 

  74. Hall P, Holm LE, Lundell G, Ruden BI. Tumors after radiotherapy for thyroid cancer. Acta Oncol. 1992;31:403–7.

    Article  CAS  PubMed  Google Scholar 

  75. Sasse AD, Clark LG, Sasse EC, et al. Amifostine reduced side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2006;64:784–91.

    Article  CAS  PubMed  Google Scholar 

  76. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S–2-(3-amiopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose 131I treatment: results obtained in a rabbit animal model and in a double blind multi-arm trial. Cancer Biother Radiopharm. 1999;13:337–47.

    Article  Google Scholar 

  77. Kim SJ, Choi HY, Kim IJ, et al. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131I-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid. 2008;18:325–31.

    Article  CAS  PubMed  Google Scholar 

  78. Schuchter L, Meropol NJ, Winer EP, et al. Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol. 2003;4:593.

    Article  PubMed  Google Scholar 

  79. Levy HA, Park CH. Effect of reserpine on salivary gland 131I uptake in thyroid cancer. Clin Nucl Med. 1987;12:303–7.

    Article  CAS  PubMed  Google Scholar 

  80. Bhartiya US, Raut YS, Joseph LJ, Hawaldar RW, Rao BS. Evaluation of the radioprotective effect of turmeric extract and vitamin E in mice exposed to therapeutic dose of radioiodine. Indian J Clin Biochem. 2008;23:382–6.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Leban JJ, Bhartiya U, Raut YS, et al. Radioprotective effect of Ocimum sanctum and amifostine on the salivary gland of rats after therapeutic radioiodine exposure. Cancer Biother Radiopharm. 2011;26:737–43.

    Article  CAS  Google Scholar 

  82. Koca G, Gültekin SS, Han Ü, Kuru S, Demirel K, Korkmaz M. The efficacy of montelukast as a protective agent against 131I-induced salivary gland damage in rats: scintigraphic and histopathological findings. Nucl Med Commun. 2013;34:507–17.

    Article  CAS  PubMed  Google Scholar 

  83. Noaparast Z, Hosseinimehr J. Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Futur Oncol. 2013;9:1145–59.

    Article  CAS  Google Scholar 

  84. Kim HW, Ahn BY, Lee SW, Lee J. Effect of parotid gland massage on parotid gland Tc-99m pertechnetate uptake. Thyroid. 2012;22:611–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Freitas JE, Gross MD, Ripley S, Shapiro B. Radionuclide diagnosis and therapy of thyroid cancer; current status report. Semin Nucl Med. 1985;15:106–31.

    Article  CAS  PubMed  Google Scholar 

  86. Nakada K, Ishibashi T, Takei K, et al. Does lemon candy decrease salivary gland damage following 131I therapy for thyroid cancer? J Nucl Med. 2005;46:261–6.

    PubMed  Google Scholar 

  87. Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients; a prospective, randomized, single-blind, controlled trial. J Nucl Med. 2010;51:618–23.

    Article  CAS  PubMed  Google Scholar 

  88. Jentzen W, Balschuweit D, Schmitz J, et al. The influence of salivary flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET/CT imaging. Eur J Nucl Med Mol Imaging. 2010;37:2298–306.

    Article  CAS  PubMed  Google Scholar 

  89. Van Nostrand D, Bandaru V, Chennupati V, Kulkarni K, Wexler J, Atkins F, Mete M, Gadwale G. Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. Thyroid. 2010;20:1113–9.

    Article  PubMed  CAS  Google Scholar 

  90. Kulkarni K, Van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L. Does lemon juice increase radioiodine re-accumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun. 2014;35:210–6.

    Article  CAS  PubMed  Google Scholar 

  91. Nahlieli O, Nazarian Y. Sialadenitis following radioiodine therapy—a new diagnostic and treatment modality. Oral Dis. 2006;12:476–9.

    Article  CAS  PubMed  Google Scholar 

  92. Bomeli ST, Schaitkin B, Carrau RL, et al. Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. Laryngoscope. 2009;119:864–7.

    Article  PubMed  Google Scholar 

  93. Varma VM, Dai WL, Henkin RI. Taste dysfunction in patients with thyroid cancer following treat with I-131. J Nucl Med. 1992;33:996.

    Google Scholar 

  94. Orquiza M, Khorjekar G, Schneider M, Kulkarni K, Garcia C, Acio E, Burman K, Wartofsky L, Van Nostrand D. Altered and/or loss of taste after 131I therapy: the frequency, time of onset, severity, and duration. J Nucl Med. 2014;55:1933.

    Google Scholar 

  95. Norby EH, Neutze JH, Van Nostrand D, et al. Nasal radioactive iodine uptake: a prospective study of frequency, intensity and pattern. J Nucl Med. 1990;31:52–4.

    CAS  PubMed  Google Scholar 

  96. Levenson D, Coulec S, Sonnenberg M, et al. Peripheral facial nerve palsy after high-dose 131I therapy in patients with papillary thyroid carcinoma. Ann Intern Med. 1994;120:576–8.

    Article  CAS  PubMed  Google Scholar 

  97. Burmeister LA, du Cret RP, Mariash CN. Local reaction to 131I in the treatment of thyroid cancer. Am J Med. 1991;90:217–22.

    Article  CAS  PubMed  Google Scholar 

  98. Cherk MH, Yap KV, Topliss BM, et al. Acute radiation thyroiditis that sometimes occurs with post-thyroidectomy remnant ablation is directly related to thyroidal 131I uptake and not to the amount of 131I used for ablation. Clin Thyroidology. 2009;21:24–6.

    Google Scholar 

  99. Goolden AWG, Kam KC, Fitzpatrick ML, Munro AJ. Oedema of the neck after ablation of the thyroid with radioactive iodine. Br J Radiol. 1986;59:583–6.

    Article  CAS  PubMed  Google Scholar 

  100. Cooper DS, Ridgway EC, Maloof F. Unusual types of hyperthyroidism. Clin Endocrinol Metab. 1978;7:199–220.

    Article  CAS  PubMed  Google Scholar 

  101. Smith R, Blum C, Benua RS, Fawwaz R. Radioactive iodine treatment of metastatic thyroid carcinoma with clinical thyrotoxicosis. Clin Nucl Med. 1985;10:874–5.

    Article  CAS  PubMed  Google Scholar 

  102. Ikejiri K, Furuyama M, Muranaka T, et al. Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis. Clin Nucl Med. 1997;22:227–30.

    Article  CAS  PubMed  Google Scholar 

  103. Trunnell JB, Marinelli LD, Duffy Jr BJ, et al. The treatment of metastatic thyroid cancer with radioactive iodine: credits and debits. J Clin Endocrinol. 1949;9:1138–52.

    Article  CAS  Google Scholar 

  104. Cerletty JM, Listwan WJ. Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA. 1979;242:269–70.

    Article  CAS  PubMed  Google Scholar 

  105. Winslow CP, Meyers AD. Hypocalcemia as a complication of 131I therapy. Am J Otolaryngol. 1998;19:401–3.

    Article  CAS  PubMed  Google Scholar 

  106. Glazebrook GA. Effect of decicurie prescribed activity of radioactive I-131 on parathyroid function. Am J Surg. 1987;154:368–73.

    Article  CAS  PubMed  Google Scholar 

  107. Zhu R, Yu Y, Lu H. Clinical study of 312 cases with metastatic differentiated thyroid cancer treated with large doses of 131I. Chin Med J. 2005;118:425–8.

    PubMed  Google Scholar 

  108. Cunha DDS, Izilda MI, Simōes P, et al. Carotid artery rupture following radioiodine therapy for differentiated thyroid carcinoma. Arq Bras Endocrinol Metab. 2011;55:419–25.

    Article  Google Scholar 

  109. Lee TC, Harbert JC, Dejter SW, et al. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant. J Nucl Med. 1985;26:49–50.

    CAS  PubMed  Google Scholar 

  110. Pochin EE. 131I treatment of thyroid cancer. In: Hahn PF, editor. Therapeutic use of artificial radioisotopes. New York: Wiley; 1956. p. 195.

    Google Scholar 

  111. Fajardo L-GLF, Berthrong M, Anderson RE, editors. Radiation pathology. Oxford: University Press; 2001.

    Google Scholar 

  112. Gomez D, Rosenzweig KE. Lung. In: Shrieve DC, Loeffler JS, editors. Human radiation injury. Philadelphia: Wolters Kluwer; 2011. p. 306–15.

    Google Scholar 

  113. Rall JE, Alpers JB, Lewallen CG, et al. Radiation pneumonitis and fibrosis: a complication of 131I treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab. 1957;17:1263–76.

    Article  CAS  PubMed  Google Scholar 

  114. Tollefsen HR, DeCosse JJ, Hutter RVP. Papillary carcinoma of the thyroid. A clinical and pathological study of 70 fatal cases. Cancer. 1964;17:1035–43.

    Article  CAS  PubMed  Google Scholar 

  115. Aldrich LB, Sisson JC, Grum CM. Pulmonary function in thyroid carcinoma metastatic to the lung. J Endocrinol Invest. 1987;10:111–6.

    Article  CAS  PubMed  Google Scholar 

  116. Menzel C, Grunwald F, Schomburg A, et al. “High-dose” 131I therapy in advanced differentiated thyroid carcinoma. J Nucl Med. 1996;37:1496–503.

    CAS  PubMed  Google Scholar 

  117. Bennett DE, Million RR, Ackerman LV. Bilateral radiation pneumonitis. A complication of the radiotherapy of bronchogenic carcinoma. Cancer. 1969;23:1001–18.

    Article  CAS  PubMed  Google Scholar 

  118. Fulkerson WJ, McLendon RE, Prosnitz LR. Adult respiratory distress syndrome after limited radiotherapy. Cancer. 1986;57:1941–6.

    Article  CAS  PubMed  Google Scholar 

  119. Monson JM, Stark P, Reily JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 1998;82:842–50.

    Article  CAS  PubMed  Google Scholar 

  120. Morgan GW, Pharm B, Breit SN. Radiation and the lung. Int J Radiat Oncol Biol Phys. 1995;31:361–9.

    Article  CAS  PubMed  Google Scholar 

  121. Delanian S, Porcher R, Rudant J, et al. Kinetics of response to long-term treatments combining pentoxifylline, and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol. 2005;23:8570–9.

    Article  PubMed  Google Scholar 

  122. Choi NC, Kanarek DJ, Kazemi H. Physiologic changes in pulmonary function after thoracic radiotherapy for patients with lung cancer and role of regional pulmonary function studies predicting postradio-therapy pulmonary function before radiotherapy. Cancer Treat Symp. 1985;2:119–30.

    Google Scholar 

  123. Mah K, Van Dyk J, Keane T, Poon PY. Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys. 1987;13:179–88.

    Article  CAS  PubMed  Google Scholar 

  124. Smith JC. Radiation pneumonitis. A review. Am Rev Respir Dis. 1963;87:647–65.

    CAS  PubMed  Google Scholar 

  125. Carmel RJ, Kaplan HS. Mantle irradiation for Hodgkin’s disease. An analysis of technique, tumor eradication and complications. Cancer. 1976;37:2813–25.

    Article  CAS  PubMed  Google Scholar 

  126. Fryer CJH, Fitzpatrick PJ, Rider WD, et al. Radiation pneumonitis: experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys. 1978;4:931–6.

    Article  CAS  PubMed  Google Scholar 

  127. McDonald S, Rubin P, Philips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys. 1995;31:1187–203.

    Article  CAS  PubMed  Google Scholar 

  128. Fowler JF, Travis EL. The radiation pneumonitis syndrome in half-body radiation therapy. Int J Radiat Oncol Biol Phys. 1978;4:1111–3.

    Article  CAS  PubMed  Google Scholar 

  129. Keane T, Van Dyk J, Rider WD. Idiopathic interstitial pneumonia following bone marrow transplantation. The relationship with total body irradiation. Int J Radiat Oncol Biol Phys. 1981;7:1365–70.

    Article  CAS  PubMed  Google Scholar 

  130. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med. 1977;86:81–92.

    Article  CAS  PubMed  Google Scholar 

  131. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab. 1985;60:376–80.

    Article  CAS  PubMed  Google Scholar 

  132. Gopal R, Tucker SI, Komaki R, et al. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 2003;56:106–13.

    Article  PubMed  Google Scholar 

  133. Wilner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameter. Strahlenther Onkol. 2003;179:548–56.

    Article  Google Scholar 

  134. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.

    Article  CAS  PubMed  Google Scholar 

  135. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–35.

    Article  CAS  PubMed  Google Scholar 

  136. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer. J Radiat Oncol Biol Phys. 1999;45:323–9.

    Article  CAS  Google Scholar 

  137. Samuel AM, Unnikrishnan TP, Baghel NS, Rajashekharrao B. Effect of 131I therapy on pulmonary alveolar-capillary membrane integrity. J Nucl Med. 1995;36:783–7.

    CAS  PubMed  Google Scholar 

  138. Schlumberger M, Arcangioli O, Piekarski JD, et al. Detection of and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays. J Nucl Med. 1988;29:1790–4.

    CAS  PubMed  Google Scholar 

  139. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with 131I. J Nucl Med. 1994;35:1418–22.

    CAS  PubMed  Google Scholar 

  140. Maheshwari YK, Strattton Hill C, Haynie TP, et al. Iodine-131 therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer. 1981;47:664–71.

    Article  CAS  PubMed  Google Scholar 

  141. Goffman T, Loff V, Tuttle M, et al. Near-lethal respiratory failure after recombinant human thyroid-stimulation hormone use in a patient with metastatic thyroid carcinoma. Thyroid. 2003;13:827–30.

    Article  PubMed  Google Scholar 

  142. Hindiè E, Melliere D, Lange F, et al. Functioning pulmonary metastases of thyroid cancer: does 131I influence the prognosis? J Nucl Med. 2003;30:974–81.

    Article  CAS  Google Scholar 

  143. Hughes JM, Lockwood DN, Jones HA, et al. DLCO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. Respir Physiol. 1991;83:155–66.

    Article  CAS  PubMed  Google Scholar 

  144. Khan JH, McElhinney DB, Rahman SB, et al. Pulmonary metastases of endocrine origin: the role of surgery. Chest. 1998;114:526–34.

    Article  CAS  PubMed  Google Scholar 

  145. Liu D, Labow D, Dang N, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol. 1999;6:572–8.

    Article  CAS  PubMed  Google Scholar 

  146. Nemec J, Zamrazil V, Pohunkova D, Roohling S. Radioiodide treatment of pulmonary metastases of differentiated thyroid cancer; results and prognostic factors. Nuklearmedizin. 1979;18:86–90.

    CAS  PubMed  Google Scholar 

  147. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer. 1984;53:982–92.

    Article  CAS  PubMed  Google Scholar 

  148. Esposito G, Van Nostrand D, Atkins F, Burman K, Wartofsky L, Kulkarni K. Frequency of “over” and “under” treatment with empiric dosage of I-131 in patients with and without lung metastasis secondary to well-differentiated thyroid cancer. J Nucl Med. 2006;47(1):238P. abstract.

    Google Scholar 

  149. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47:1587–91.

    PubMed  Google Scholar 

  150. Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid. 2006;16:1019–23.

    Article  CAS  PubMed  Google Scholar 

  151. Khorjekar G, Van Nostrand D, Vetter R, Ringel M, Carter E, Bloom G. The frequency of vomiting after outpatient I-131 therapy in patients with well-differentiated thyroid cancer. J Nucl Med. 2010;51S:1580. abstract.

    Google Scholar 

  152. Khorjekar G, Van Nostrand D, Vetter R, Ringel M, Carter E, Bloom G. The relationship of several factors and vomiting after outpatient I-131 treatment in pts with well-differentiated thyroid cancer. J Nucl Med. 2010;51S:1570. abstract.

    Google Scholar 

  153. Quimby ES, Feitelberg S, Laughlin JS, et al. NCRP report 37: precautions in the management of patients who have received therapeutic amounts of radionuclides. Washington, DC: National Council on Radiation Protection; 1970.

    Google Scholar 

  154. US Nuclear Regulatory Commission. Criteria for release of individuals administered radioactive materials. Fed Regist. 1997;62:4120.

    Google Scholar 

  155. Kinuya S, Hwang E, Ikeda E, et al. Mallory-Weiss Syndrome caused by iodine-131 therapy for metastatic thyroid carcinoma. J Nucl Med. 1997;38:1831–2.

    CAS  PubMed  Google Scholar 

  156. Balan KK, Raouf AH, Critchley M. Outcome of 249 patients attending a nuclear medicine department with well-differentiated thyroid cancer; a 23 year review. Br J Radiol. 1994;67:283–91.

    Article  CAS  PubMed  Google Scholar 

  157. Dobyns BM, Maloof F. The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. J Clin Endocrinol. 1951;11:1323–60.

    Article  CAS  Google Scholar 

  158. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk—adapted approach. J Nucl Med. 2003;44:451–6.

    CAS  PubMed  Google Scholar 

  159. Grunwald F, Schomburg A, Menzel C, et al. Blood count changes after 131I treatment in thyroid carcinoma. Med Klin. 1994;89:522–8.

    CAS  Google Scholar 

  160. Haynie T, Beierwaltes W. Hematologic changes observed following therapy for thyroid carcinoma. J Nucl Med. 1963;4:85–91.

    CAS  PubMed  Google Scholar 

  161. Keldsen N, Mortensen BT, Hansen HS. Bone marrow depression due to I-131 treatment of thyroid cancer. Ugeskr Laeger. 1988;50:2817–9.

    Google Scholar 

  162. Matthies A, Bender H, Distelmaier M, et al. Efficacy and side effects of high dose iodine-131 therapy in metastatic thyroid carcinoma. Eur J Nucl Med. 2004;45S:189P.

    Google Scholar 

  163. Molinaro E, Leboeuf R, Shue B, et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid. 2009;19:1035–41.

    Article  PubMed  Google Scholar 

  164. Petrich T, Widjaja A, Musholt TJ, et al. Outcome after 131I therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur J Nucl Med. 2001;28:203–8.

    Article  CAS  PubMed  Google Scholar 

  165. Robeson WR, Ellwood JE, Margulies P, Margouleff D. Outcome and toxicity associated with maximum safe dose 131I treatment of metastatic thyroid cancer. Clin Nucl Med. 2002;27:556–666.

    Article  PubMed  Google Scholar 

  166. Schober O, Gunter HH, Schwarzrock R, Hundeshagen H. Hamatologische langzeitveranderungen bei der Radiojodtherapie des Schilddrusenkarzinoms. Strahlenther Onkol. 1987;163:464–74.

    CAS  PubMed  Google Scholar 

  167. Schumichen C, Schmitt E, Scheuffele C. Influence of the therapy concept onto the prognosis of thyroid carcinoma. Nuklearmedizin. 1983;22:97–105.

    CAS  PubMed  Google Scholar 

  168. Kuhn JM, Rieu M, Wolf LM, et al. Hematologic repercussions of disorders of thyroid secretion. Presse Med. 1984;13:421–5.

    CAS  PubMed  Google Scholar 

  169. Donate RM, Gallagher NI. Hematologic alteration associated with endocrine disease. MedClin N Am. 1968;52:231–41.

    Google Scholar 

  170. Leeper 1980. Personal communication.

    Google Scholar 

  171. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989;69:186–90.

    Article  CAS  PubMed  Google Scholar 

  172. Vini L, Hyer S, Al-Saadi A, et al. Prognosis for fertility and ovarian function after treatment with 131I for thyroid cancer. Postgrad Med J. 2002;78:92–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Souza Rosario PW, Alvarenga Fagundes T, Villa-Boas Fagundes AS, et al. Ovarian function after 131I therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes. 2005;113:331–3.

    Article  CAS  PubMed  Google Scholar 

  174. Ceccarelli C, Bencivelli W, Morciano D, et al. I-131 therapy for differentiated thyroid cancer leads to an earlier onset of menopause; results of a retrospective study. J Clin Endocrinol Metab. 2001;86:3512–5.

    Article  CAS  PubMed  Google Scholar 

  175. Rosario PW, Fagundes TA, Fagundes AV, et al. 131I therapy and age at menopause in patients with thyroid cancer. Clin Endocrinol (Oxf). 2006;64:225–6.

    Article  Google Scholar 

  176. Wichers M, Benz E, Palmedo H, et al. Testicular function after 131I therapy for thyroid carcinoma. Eur J Nucl Med. 2000;27:503–7.

    Article  CAS  PubMed  Google Scholar 

  177. Hyer S, Vini L, O’Connell M, et al. Testicular dose and fertility in mean following I-131 therapy for thyroid can. Clin Endocrinol. 2002;56:755–8.

    Article  CAS  Google Scholar 

  178. Handelsman DJ, Turtle JR. Testicular damage after radioactive iodine therapy for thyroid cancer. Clin Endocrinol. 1983;18:465–72.

    Article  CAS  Google Scholar 

  179. Rosario PW, Barroso AL, Rezende LL, et al. Testicular function after 131I therapy in patients with thyroid cancer. Thyroid. 2006;16:667–70.

    Article  CAS  PubMed  Google Scholar 

  180. Esfahani AF, Eftekhari M, Zenooz N, et al. Gonadal function in patients with differentiated thyroid cancer treated with I-131. Hell J Nucl Med. 2004;7:52–5.

    PubMed  Google Scholar 

  181. Garsi J-P, Schlumberger M, Rubino C, et al. Therapeutic administration of I-131 for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med. 2008;49:845–52.

    Article  PubMed  Google Scholar 

  182. Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancies in female cancer survivors. Clin Endocrinol. 2008;69:479–90.

    Article  Google Scholar 

  183. Sioka C, Fotopoulos A. Effects of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer. Fertil Steril. 2011;95:1552–9.

    Article  CAS  PubMed  Google Scholar 

  184. Garsi J-P, Schlumberger M, Ricard M, et al. Health outcomes of children fathered by patients treated with 131I for thyroid cancer. Clin Endocrinol. 2009;71:880–3.

    Article  CAS  Google Scholar 

  185. Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol. 2008;68:610–7.

    Article  Google Scholar 

  186. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  PubMed  Google Scholar 

  187. Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by 131I I-131: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335–46.

    Article  PubMed  Google Scholar 

  188. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6th ed. Philadelphia: Lippincott William & Wilkins; 2006.

    Google Scholar 

  189. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17:1277–88.

    Article  PubMed  Google Scholar 

  190. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504–15.

    Article  CAS  PubMed  Google Scholar 

  191. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after 131I treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19:451–7.

    Article  CAS  PubMed  Google Scholar 

  193. Gandhi S, Abhyankar A, Basu S. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables. Nucl Med Commun. 2014;35:205–9.

    Article  CAS  PubMed  Google Scholar 

  194. Lang BH, Wong KP. Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma. Ann Surg Oncol. 2011;18:3559–65.

    Article  PubMed  PubMed Central  Google Scholar 

  195. Fallahi B, Adabi K, Majidi M, et al. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to 131I treatment. Clin Nucl Med. 2011;36:277–82.

    Article  PubMed  Google Scholar 

  196. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive 131I therapy. Cancer. 2011;117:4439–46.

    Article  PubMed  PubMed Central  Google Scholar 

  197. Taïeb D, Sebag F, Farman-Ara B, et al. Iodine biokinetics and 131I exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2010;95:3283–90.

    Article  PubMed  CAS  Google Scholar 

  198. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with 131I. Br J Radiol. 1986;59(697):45–51.

    Article  CAS  PubMed  Google Scholar 

  199. Ishikawa K, Noguchi S, Tanaka K, Fukuda A, Hirohata T. Second primary neoplasms in thyroid cancer patients. Jpn J Cancer Res. 1996;87:232–9.

    Article  CAS  PubMed  Google Scholar 

  200. Kita T, Yokoyama K, Higuchi T, Kinuya S, Taki J, Nakajima K, Michigishi T, Tonami N. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 for differentiated thyroid carcinoma. Ann Nucl Med. 2004;18:345–9.

    Article  PubMed  Google Scholar 

  201. Leeper RD. The effect of I-131 therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973;36:1143–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

My deepest thanks go to the many patients who have given generous donation to help underwrite the research studies that have been performed at the MedStar Washington Hospital Center regarding the side effects of 131I therapy.

In addition, my personal gratitude also goes to Kristen L. Blair, RDH (Registered Dental Hygienist), and Janice Falvo, BS, RDH (Registered Dental Hygienist), for not only their input to this chapter regarding the value of a dental hygienist but also for managing some of my post 131I therapy patients.

Author information

Authors and Affiliations

  1. Nuclear Medicine Research, MedStar Research Institute and Washington Hospital Center, Georgetown University School of Medicine, Washington Hospital Center, 110 Irving Street, N.W., Suite GB 60F, Washington, DC, 20010, USA

    Douglas Van Nostrand MD, FACP, FACNM

  2. Department of Radiology, St. Joseph Mercy Health System, Ypsilanti, MI, USA

    John E. Freitas MD

  3. Division of Endocrinology and Metabolism, Department of Medicine, University Health Network – University of Toronto/Toronto General Hospital, Toronto, ON, Canada

    Anna M Sawka MD, PhD

  4. Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada

    Richard W. Tsang MD, FRCP(C)

Authors
  1. Douglas Van Nostrand MD, FACP, FACNM
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John E. Freitas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna M Sawka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard W. Tsang MD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Van Nostrand MD, FACP, FACNM .

Editor information

Editors and Affiliations

  1. Department of Medicine, MedStar Washington Hospital Center Georgetown University School of Medicine, Washington, DC, USA

    Leonard Wartofsky

  2. Nuclear Medicine Research MedStar Research Institute and Washington Hospital Center, Georgetown University School of Medicine Washington Hospital Center, Washington, DC, USA

    Douglas Van Nostrand

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Van Nostrand, D., Freitas, J.E., Sawka, A.M., Tsang, R.W. (2016). Side Effects of 131I for Therapy of Differentiated Thyroid Carcinoma. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3314-3_62

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3314-3_62

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3312-9

  • Online ISBN: 978-1-4939-3314-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation